BETHESDA, Md. (August 12, 2026) Precision AQ, a global commercialization partner built to guide life science innovators through commercial complexity, today announced the appointment of Candice Subero as Senior Vice President of Marketing. Ms. Subero joins Precision AQ during a period of significant growth and industry recognition, including recent finalist honors for both Medical Marketing Agency of the Year and Medical Communications Agency of the Year in the 2026 MM+M Awards.
Ms. Subero brings more than 20 years of experience building and scaling marketing organizations across healthcare, life sciences, diagnostics, and healthcare technology. Most recently, she served as Vice President of Global Marketing at OPEN Health, where she helped strengthen the company's commercial platform through integrated marketing, demand generation, brand transformation, thought leadership, and customer engagement initiatives.
At Precision AQ, Ms. Subero joins a connected Go-To-Market Commercial Office that spans Marketing, Lead Generation, Sales, Proposals, Strategy and Operations. In her role, Ms. Subero will lead the Marketing and Lead Generation functions, building a strategic engine that combines thought leadership, account-based marketing, customer engagement, and AI-powered demand generation to strengthen pipeline creation and drive scalable growth across the organization.
"What excites me most about Precision AQ is the opportunity to join an organization that has reimagined what a modern commercial partner can be for healthcare innovators,” said Ms. Subero. “Precision has built a uniquely connected model that combines deep therapeutic expertise, end-to-end commercialization capabilities, and powerful data and analytics to support clients from early development through launch and loss of exclusivity. Rather than approaching challenges through disconnected functions, Precision AQ is organized around the needs of clients and the realities of the healthcare ecosystem, helping companies translate scientific innovation into meaningful patient impact. I look forward to working across the organization to strengthen customer engagement, scale our market presence, accelerate growth, and continue building differentiated solutions that help our clients succeed.”
"Candice joins Precision AQ at an important moment in our journey," said Daniel Cummings, Chief Commercial Officer at Precision AQ. "Over the last 15 months, we have built a connected commercial operating system that brings together marketing, lead generation, sales, proposals, strategy, and customer engagement around a single goal: delivering Precise Commercialization by connecting biopharmaceutical companies with the right expertise, capabilities, and insights at the right moments across the product lifecycle. By helping clients navigate complexity and maximize the impact of innovation, we create stronger outcomes for our clients and drive sustainable growth for our business. Candice's experience scaling marketing organizations, driving commercial adoption, and creating alignment across complex healthcare businesses will help us accelerate our momentum, as we continue investing in client-centric innovation, AI-enabled execution, and marketing as a strategic business driver."
Candice's appointment reflects Precision AQ's continued investment in strengthening its commercial platform and advancing its vision for Precise Commercialization. As healthcare innovators face increasing complexity across development, launch, access, and commercialization, Precision AQ is focused on helping biopharmaceutical companies translate innovation into impact through integrated strategy, evidence generation, commercialization, market access, and customer engagement capabilities. By bringing these disciplines together, the company helps clients navigate critical decisions, accelerate adoption, and improve outcomes for the patients they serve.
Precision AQ is the commercialization partner of choice for biopharma innovators, market access leaders, and brand strategists. Trusted by all 30 of the world’s top pharmaceutical companies and leading biotechs, we specialize in transforming complex data into clear, actionable strategies that accelerate access to innovation, including launching 450+ drugs across all therapeutic areas. At Precision AQ, we believe access is enabled by evidence, empathy, and precision. For more information, visit www.precisionaq.com.
Contact:
Hannah Deresiewicz
Precision AQ
hannah.deresiewicz@precisionaq.com